

# Investor Newsletter

Issue **05** 2020





## Skywalker™ Orthopedic Surgical Robot Becomes the Nineteenth Product of MicroPort® to Enter “Green Path”

On May 21, 2020, Skywalker™ Orthopedic Surgical Robot (also known as “Joint Replacement Robot”), which is developed by Suzhou MicroPort OrthoBot Co., Ltd. (“MicroPort® OrthoBot”), was granted entry into the Special Review Procedure for Innovative Medical Devices (“Green Path”) of National Medical Products Administration of China (NMPA). The product has become the 19th product of MicroPort® or its related companies to enter the Green Path. MicroPort® OrthoBot is a subsidiary of MicroPort® MedBot (Shanghai) Co., Ltd. (“MicroPort® MedBot”).



Skywalker™ Orthopedic Surgical Robot is a surgical robotic system indicated for use in total knee arthroplasty. Compared to conventional joint arthroplasty, the robotic-assisted arthroplasty can help orthopedic healthcare professionals tackle the long-lasting issues complicating the procedures, such as hindered view, vague cutting and unstable instrument holding, to achieve higher operational precision. Skywalker™ Orthopedic Surgical Robot is composed of surgical platform, navigation console and surgical accessories. It provides a novel and complete solution in pre-operative diagnosis and intra-operative aspects including safety, convenience and interactive experience.

Thus far, no Chinese-made joint replacement robot indicated for the same use has been launched in China. The entry of Skywalker™ Orthopedic Surgical Robot into the Green Path is set to shorten its time to market and further speed up the clinical promotion of robotic-assisted arthroplasty techniques, so as to drive the development of relevant industry chain in China to eventually benefit more patients.



## Endovastec™ Receives Registration Certificate for Reewarm™ PTX Drug Coated Balloon PTA Catheter in China

Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”) recently received the registration certificate for Reewarm™ PTX Drug Coated Balloon PTA Catheter (“Reewarm™ PTX Drug Coated Balloon”) from National Medical Products Administration of China (NMPA). Reewarm™ PTX Drug Coated Balloon is the third device of Endovastec™ that wins the regulatory approval after being granted the entry into the Special Review and Approval Procedure for Innovative Medical Devices (“Green Path”) of NMPA. Thus far, a total of five devices of Endovastec™ have entered the “Green Path”, including Castor® Branched Aortic Stent-Graft System, which is the world’s first of its likes and obtained regulatory approval in June 2017, and Minos® Ultra Low-Profile AAA Stent-Graft System, which won the approval in March 2019.

The approval for Reewarm™ PTX Drug Coated Balloon, which is a heavyweight product of Endovastec™ in the area of peripheral artery disease treatment, has further enriched the company’s current product range.” In the future, Endovastec™ will continue to follow the R&D rationale featuring ceaseless innovation to further perfect its product portfolio in the area of peripheral vascular intervention, so as to provide patients with high-quality and inaccessible medical solutions that can improve their quality of life.





## MicroPort® Orthopedics Group Brings in **New Strategic Investors**

On May 13, 2020, MicroPort Scientific Corporation (“MicroPort”) announced that Suzhou MicroPort Orthopedic Scientific (Group) Co. Ltd. (“MicroPort® Orthopedics Group”), which is an orthopedics business-focused subsidiary of MicroPort®, has entered into funding agreements with several prominent strategic investors to raise 580 million yuan as planned previously. The investors include China Life Healthcare Investment Fund, E Fund Asset Management, Yuemintou Asset Management and CQY Capital.

With its inception dating back to 2009, MicroPort® Orthopedics Group has achieved the global operation of the orthopedics business and grown to be (one of) the biggest orthopedics companies in China by undertaking more than a decade of independent R&D and highly efficient integration of global resources and markets. MicroPort® Orthopedics Group has a registered capital of about 2.2 billion yuan, with its products marketed in more than 60 countries and regions and offices located in a number of major cities across the world.


The capital injection of external investors in MicroPort® Orthopedics Group, along with their active participation in the building of a modern corporate governance structure, has laid a good groundwork for the independent and standardized operation of MicroPort® Orthopedics Group. It marks a promising beginning from which MicroPort® Orthopedics Group will take further advantage of a broader capital market to achieve expedited development to provide global patients with accessible therapeutic solutions based on the most advanced medical technologies.




## MicroPort® and NDR, a Developer of Automated Needle Targeting Robotics System, Announce **Strategic Investment and Agreement** to Establish a Joint Venture in China

On May 6, 2020, MicroPort Scientific Corporation ("MicroPort®") announced that it has entered into definitive agreements with Singapore-based NDR Medical Technology Private Limited ("NDR") to lead a strategic investment of SGD8 million in NDR in a Series A round of funding. Other investors include SGInnovate and Kava Ventures. Meanwhile, MicroPort Urocare (Jiaxing) Co., Ltd. ("MicroPort® Urocare"), which is a subsidiary of MicroPort®, has also entered into an agreement with NDR to set up a joint venture to market, manufacture and locally develop NDR's products in the Greater China. The Automated Needle Targeting (ANT) robotics system developed by NDR is indicated for use in percutaneous lung biopsy and percutaneous nephrolithotomy (PCNL) procedures. The partnership is expected to further expand the product range of MicroPort® in the fields of respiratory intervention and urological intervention.

Founded in 2014, NDR is a medical device company incorporated in Singapore which has developed the Automated Needle Targeting (ANT) robotics system that combines artificial intelligence (AI) and medical image processing for needle positioning, used in the percutaneous puncture procedures for kidney, lung and other organs. The ANT-X robotics system, another product developed by NDR, is indicated for percutaneous nephrolithotomy (PCNL) procedures. The precise needle positioning is the most critical step in PCNL. Compared to conventional manual needle positioning, the application of the ANT-X robotics system could reduce the complexity, shorten physicians' learning curve, increase procedure accuracy and minimize complications, which will benefit the patients with kidney stone and ureteral stone.







## MicroPort® Attends 2020 CTO Week

Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 2020 CTO Week & Mayday - Appointment of Conquering CTO and sponsored multiple symposiums. The event was held online to provide domestic and international CTO operators with a 5-day scientific feast on CTO-PCI.

During the 2020 CTO Week, MicroPort® sponsored the National Is International - CTO WEEK MicroPort® Evening Interview. The key opinion leaders including Academician Runlin Gao spoke of their experiences in the practice of medicine and introduced the development history of CTO techniques in China. MicroPort® also sponsored a symposium on Firefighter™ Balloon under the theme of Pioneer of Unique Innovation: the Past and Present of Chinese-made Balloons and discussed the performance and clinical advantages of Firefighter™ Balloon.

The 2020 CTO Week provided an opportunity and a platform for physicians to have scientific exchanges during the COVID-19 pandemic. In the future, MicroPort® will continue its past practice to communicate most up-to-date scientific information and share clinical expertise. MicroPort® will promote the scientific exchanges in the field of CTO treatment in China, so as to provide doctors and patients with more integrated therapeutic solutions that can prolong and transform lives.



## MicroPort® Attends the 23rd Edition of China Cardiovascular Intervention Forum (CCIF2020 Online)

Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort”) recently attended the 23rd Edition of China Cardiovascular Intervention Forum (CCIF2020 Online). Due to the COVID-19 pandemic, the CCIF2020 was held online to provide the national interventional cardiologists with a brand new method for scientific exchanges. MicroPort® sponsored a live case session titled Micro-procedure - Discussions on Surgical Strategies for Cardiovascular Intervention and Therapeutic Solutions to Highly Dangerous and Complex Cases.

The “Micro-procedure” Live Case session was well received during the CCIF2020 online. The physicians remarked that the new model had helped build a convenient and efficient platform for the scientific exchanges of clinicians and contributed to the improvement in their scientific knowledge and clinical skills. In the future, MicroPort® will continue to proactively implement the strategic transformation driven by digital technologies and vigorously promote the application of specialized online education platform such as “Micro-procedure” that follows the trend of online education in a digital era, so as to contribute to the development of China’s interventional cardiology.



# Investor Newsletter

Issue **05** 2020



For more information, please contact:

**Martin Sun**

Chief Financial Officer  
MicroPort Scientific Corporation

**Tel:** (86)(21) 38954600

**Email:** [ir@microport.com](mailto:ir@microport.com)

**Leanne Li**

Board Secretary & Vice President  
MicroPort Scientific Corporation

**Tel:** (86)(21) 38954600

**Email:** [ir@microport.com](mailto:ir@microport.com)